Scott Jeffers
Hoofd Techniek/Wetenschap/O&O bij GENSIGHT BIOLOGICS S.A.
Oorsprong van het eerstegraads netwerk van Scott Jeffers
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 18 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Scott Jeffers via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| IPSEN | Pharmaceuticals: Major | Comptroller/Controller/Auditor | |
Biologics Consulting Group, Inc.
 Biologics Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Biologics Consulting Group, Inc. provides regulatory and product development advisory services for drugs and device products. It specializes in the preparation and review of CBER, CDER and CDRH regulatory applications, facility inspection, process validation packages, and electronic submissions. The company was founded by James G. Kenimer in 1993 and is headquartered in Alexandria, VA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| REGENXBIO INC. | Pharmaceuticals: Major | General Counsel | |
| MAINSTAY MEDICAL INTERNATIONAL | Medical Specialties | Director/Board Member | |
| Wayne State University (Michigan) | College/University | Undergraduate Degree | |
| BAVARIAN NORDIC A/S | Pharmaceuticals: Major | General Counsel | |
Sofinnova Partners SAS
 Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
| The University of Chicago | College/University | Doctorate Degree | |
| Suffolk University | College/University | Undergraduate Degree | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Director of Finance/CFO | |
| MAUNA KEA TECHNOLOGIES | Medical Specialties | Chief Tech/Sci/R&D Officer | |
| University of Warwick | College/University | Undergraduate Degree | |
| GENFIT | Pharmaceuticals: Major | General Counsel | |
| Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree | |
| Sciences Po | College/University | Graduate Degree | |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | General Government | Corporate Officer/Principal | |
| Ecole Polytechnique | College/University | Undergraduate Degree | |
France Biotech Association
 France Biotech Association Miscellaneous Commercial ServicesCommercial Services France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin. | Miscellaneous Commercial Services | Director/Board Member | |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| RAPTOR PHARMACEUTICAL CORP | Pharmaceuticals: Major | Corporate Officer/Principal | |
| Sorbonne Université | College/University | Graduate Degree | |
| Ecole Supérieure de Gestion et Finances | College/University | Graduate Degree | |
| Neu-Ulm University of Applied Sciences | College/University | Masters Business Admin | |
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Biotechnology | Corporate Officer/Principal | |
Raptor Pharmaceuticals Europe BV
 Raptor Pharmaceuticals Europe BV Miscellaneous Commercial ServicesCommercial Services Part of Amgen, Inc., Raptor Pharmaceuticals Europe BV is a Dutch company that engages in research and experimental development in other physical and natural sciences. The company is based in Louveciennes, the Netherlands. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Académie nationale de Pharmacie | Corporate Officer/Principal | ||
| Ecole Polytechnique De L'universite Paris-sud | College/University | Undergraduate Degree | |
American Society of Gene & Cell Therapy
 American Society of Gene & Cell Therapy Miscellaneous Commercial ServicesCommercial Services The American Society of Gene & Cell Therapy is a medical and professional organization that represents researchers and scientists devoted to the discovery of gene and cell therapies. The American company was founded by Mark A. Kay. | Miscellaneous Commercial Services | Director/Board Member | |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member | |
| NEOMA Business School | College/University | Graduate Degree | |
Bamboo Therapeutics, Inc.
 Bamboo Therapeutics, Inc. BiotechnologyHealth Technology Bamboo Therapeutics, Inc. develops gene therapy products for central nervous system and neuromuscular diseases. Its therapeutic platform is based on the use of Adeno-associated virus as a gene therapy vehicle. The company’s proprietary technologies include chimeric vectors, self-complementary vectors, and dual glycan receptor. It focuses on the treatment of Duchenne muscular dystrophy, giant axonal neuropathy, Friedreich ataxia, and Canavan disease. Bamboo Therapeutics was founded by Richard Jude Samulski, Sheila A. Mikhail, Josh Grieger, Xiao Xiao, and Paola Leone in December 2014 and is headquartered in Chapel Hill, NC. | Biotechnology | General Counsel | |
StrideBio, Inc.
 StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Biotechnology | Corporate Officer/Principal | |
| IQVIA | Corporate Officer/Principal | ||
| X4 PHARMACEUTICALS, INC. | Biotechnology | Chairman Director/Board Member | |
| Standards Coordinating Body | Director/Board Member | ||
GFAL Ltd.
 GFAL Ltd. Real Estate Investment TrustsFinance Part of GGL Group Number Two Ltd., GFAL Ltd. is a British company that provides property investment services. The company is based in London, UK and was founded in 2015. | Real Estate Investment Trusts | Chief Executive Officer | |
| Universite Paris Cite | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| Advanced Therapies Partners LLC | President | ||
| Université Paris-Saclay | College/University | Doctorate Degree | |
Mainstay Medical Holdings Plc
 Mainstay Medical Holdings Plc Financial ConglomeratesFinance Mainstay Medical Holdings Plc is a medical device company, which focuses on commercializing an innovative implantable restorative neurostimulation system, ReActiv8, for people with disabling mechanical Chronic Low Back Pain. The company was founded in 2020 and is headquartered in Dublin, Ireland. | Financial Conglomerates | Director/Board Member | |
| Healthtech For Care | Corporate Officer/Principal | ||
Priothera SAS
 Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Biotechnology | Founder | |
| Life Sciences Acceleration Alliance eV | Director/Board Member | ||
| Celestial Consulting & Coaching | Founder |
Statistieken
Internationaal
| Frankrijk | 21 |
| Verenigde Staten | 18 |
| Duitsland | 5 |
| Verenigd Koninkrijk | 4 |
| Nederland | 3 |
Sectoraal
| Health Technology | 20 |
| Consumer Services | 16 |
| Commercial Services | 5 |
| Finance | 4 |
| Government | 2 |
Operationeel
| Director/Board Member | 53 |
| Corporate Officer/Principal | 28 |
| Chairman | 24 |
| Independent Dir/Board Member | 19 |
| Founder | 17 |
Sterkste connecties
| Insiders | |
|---|---|
| Bernard Gilly | 32 |
| Michael Wyzga | 31 |
| Maritza McIntyre | 14 |
| Elsy Boglioli Hofman | 14 |
| Cédric Moreau | 14 |
| Peter Goodfellow | 13 |
| Philippe Motté | 8 |
| Françoise de Craecker | 6 |
| Simone Seiter | 6 |
| Leigh Shaw | 6 |
| Thomas Gidoin | 5 |
| Magali Taiel | 4 |
| Marion Ghibaudo | 4 |
| Sissel Rodahl | 4 |
| Julio Benedicto | 3 |
- Beurs
- Insiders
- Scott Jeffers
- Bedrijfsconnecties
